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Objectives. This study was performed to test the safety and 
efficacy of a novel bioabsorbable hemostatic puncture closure 
device deployed through an arterial sheath. 
Background. Cardiac catheterization procedures are associated 
with a risk of complications at the arterial access site. Increasing 
numbers of interventional procedures requiring large sheaths or 
intense anticoagnlation underline the need for secure, rapid 
methods of obtaining hemostasis at the time of sheath removal. 
Methods. We conducted a randomized, multicenter trial in 435 
patients undergoing cardiac catheterization or angioplasty at 
eight participating centers. In 218 patients, hemostasis was achieved 
using the device (group I); 217 patients were assigned to the manual 
pressure control group (group II). 
Results. There were no significant differences in baseline char- 
acteristics. Time to hemostasis was considerably shorter in group 
I (2.5 _+ 15.2 vs. 15.3 -+ 11.7 rain [mean -+ SD], p < 0.0001). The 
deployment success rate for the device was 96%, and 76% of group 
I patients experienced immediate (within 1 min) hemostasis. 
Complication rates were lower in group I for bleeding, hematoma 
and occurrence of any complication. There was no difference in the 
small incidence of pseudoaneurysm formation• There was no 
change in either group in the ankle/brachial systolic blood pres- 
sure index• Ultrasound follow-up studies 60 days after device 
deployment revealed complete absorption of the device in all 
cases• Subgroup analysis revealed particular benefit in patients 
undergoing interventional procedures• The administration of hep- 
arin was associated with a significantly higher complication rate 
in the manual pressure control group, whereas heparin had no 
effect on hemostasis time or complication rates in the device 
group. 
Conclusions. This sheath-deployed, bioabsorbable device pro- 
vides a safe and effective means of obtaining rapid arterial 
hemostasis after cardiac catheterization procedures. It appears to 
be particularly useful in those patients most at risk for access ite 
complications. 
(J Am Coil Cardioi 1995;25:1685-92) 
Cardiac angiographic procedures involving arterial puncture 
carry a risk of access ite complications e timated to occur in 
1% to 5% of procedures (1,2). These complications range from 
simple hematomas to significant bleeding events requiring 
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transfusion, extended hospital stay and possible surgical repair. 
The risk of significant vascular injury may be as high as 14% in 
some coronary interventional procedures, particularly those 
requiring intense anticoagulation (3). 
As a result of these pressures, there has been considerable 
interest in new methods to assist with hemostasis atthe time of 
arterial catheter removal (4). This interest may also stem from 
increasing emphasis on outpatient catheterization (5-7) and a 
desire for earlier patient mobilization (8). Recent develop- 
ments include mechanical c amps (9), an inflatable pressure 
device (10), manual pressure aids (11) and an implantable 
collagen plug (12,13). These methods have not been compared 
with each other, but data to date have indicated increased 
safety for the mechanical clamp compared with manual hemo- 
stasis only (9). 
A novel sheath-deployed, bioabsorbable h mostatic punc- 
ture closure device has been recently described and tested in 
©1995 by the American College of Cardiology 0735-1097/95/$9.50 
0735-1097(95)00101-9 
1686 KUSSMAUL ET  AL. JACC Vol. 25, No. 7 
ARTERIAL  PUNCTURE CLOSURE DEVICE  June 1995:1685-92 
Figure 1. Hemostatic puncture closure device. Inset 
shows the small (2 X 10 ram) bioabsorbable intravascular 
anchor, collagen plug (average weight 18 rag) and con- 
necting suture. 
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Europe (14) and in the United States (15). The goal of the 
present study was to investigate the safety and efficacy of this 
device compared with manual hemostasis after cardiac cathe- 
terization procedures. As a secondary goal, analysis of the 
factors contributing to bleeding after removal of arterial 
sheaths was performed. 
Methods  
Device description. The Angio-Seal hemostatic puncture 
closure device (Quinton Instrument Co.) was developed by the 
Kensey Nash Corporation. It consists of three components: a 
small fiat rectangular anchor measuring 2 x 10 ram, a bovine 
collagen plug (mean weight 18 mg) and a connecting suture. 
All three components are bioabsorbable and are contained 
within a delivery sheath (Fig. 1). The device is currently under 
investigation. 
To deploy the device, the existing arterial sheath present at 
the conclusion of the catheterization procedure is exchanged 
for an 8F sheath specially constructed to mate with the device. 
The device carrier is then inserted through this sheath (Fig. 2). 
As the tip of the device emerges from the arterial sheath, the 
anchor is exposed to arterial flow and turns perpendicular to 
the sheath. The sheath and carrier are then pulled back until 
the anchor lies flat against he interior of the artery wall and 
across the puncture site. Further withdrawal of the sheath and 
carrier as a unit pulls the collagen plug down onto the exterior 
of the arterial wall while holding the anchor against he inside 
of the wall. This results in a secure seal around the arterial wall 
defect and at the same time prevents intraarterial dep oyment 
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Figure 2. Device insertion se- 
quence: 1, Carrier sheath is in- 
serted into the arterial sheath, 
which has been pulled back several 
centimeters. 2, When fully inserted, 
the intravascular anchor protrudes 
from the end of the carrier. 3, 
Sheath and carrier are withdrawn 
as a unit, pulling the intravascular 
anchor fiat against theinside of the 
arterial wall defect. 4, Sheath and 
carrier are further withdrawn; ten- 
sion on the connecting suture 
draws the collagen plug down onto 
the outside of the arterial wall de- 
fect and exposes the tamper tube, 
which is used to gently tamp the 
collagen onto the outside of the 
artery wall. 5, A spring is attached 
to maintain light pressure on the 
tamper, and the suture is cut, al- 
lowing removal of the carrier 
sheath. 6, After 20 to 30 min, 
spring and tamper are removed, 
and suture iscut at skin level. 
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of the collagen. After removal of the sheath/carrier assembly, 
the connecting suture is exposed along with a short plastic 
tube, which is used to tamp the collagen plug onto the outside 
of the artery. Previous experience (14,15) indicates that hemo- 
stasis is immediate inmost patients. A spring is then applied to 
maintain constant, light pressure on the tamper for 15 to 
30 min. Finally, the spring is removed, and the suture is cut 
below skin level to complete the hemostasis procedure. Should 
oozing occur at this point, light pressure from one finger is 
usually sufficient o control it. A light sterile covering is 
applied. In most cases, device deployment takes <1 rain. 
Patients. Patients who were scheduled to undergo clini- 
cally indicated cardiac atheterization r angioplasty at one of 
eight participating institutions were recruited for this study. 
Five patients underwent interventional radiology procedures 
• other than cardiac atheterization. These patients were ana- 
lyzed with the patients undergoing angioplasty. 
Exclusion criteria included age <18 or >80 years, bleeding 
diathesis, warfarin therapy, thrombolytic therapy within 24 h of 
or during catheterization, acute myocardial infarction, marked 
obesity, uncontrolled hypertension a d known allergy to bo- 
vine collagen or reabsorbable suture material. Clinical or 
ultrasound evidence of significant peripheral vascular disease 
was also an exclusion criterion if any of the following were 
present: history of claudication or vascular surgery, absent 
pedal pulses, femoral artery bruit, ankle/brachial systolic blood 
pressure index <0.9 or significant (> 20% occlusive) anterior 
atherosclerosis seen on ultrasound of the common femoral 
artery. 
All patients gave written informed consent in accordance 
with policies of the institutional research review boards. 
Protocol. After screening and consent, patients underwent 
catheterization r angioplasty as clinically indicated. Attention 
was given to obtaining arterial access as cleanly as possible. If 
a hematoma developed uring the procedure, randomization 
was not performed and the patient was excluded from the 
study. In the absence of preexisting hematoma, randomization 
was carried out at the time of anticipated sheath removal by 
opening the next in a series of sealed envelopes, as described 
later. This determined whether the patient would receive the 
hemostasis device (group I) or manual compression hemostasis 
(group II), which served as the control condition. In the device 
group, strict sterile procedure was followed as the arterial 
sheath was exchanged for an 8F sheath, after which the 
hemostasis device was deployed uring arterial sheath re- 
moval. In the control group, arterial sheath removal was 
followed by hand compression (clamp compression was dis- 
couraged; 12 patients (6%) in group II underwent mechanical 
clamp hemostasis). 
Postprocedural care was identical for both groups, with 
ambulation at 4 to 12 h according to local policies and procedures. 
The randomization procedure nsured that equal numbers 
of patients would be randomized toGroups I and II by using a 
block scheme with six patients per block. The results of 
randomization were placed in sealed, sequential envelopes to 
be opened at each site as needed. 
Data gathering and follow-up. Demographic data gathered 
included relevant exclusion criteria in addition to patient age, 
gender and presence of diabetes or hypertension. Preproce- 
dural use of aspirin, heparin and other anticoagulant agents 
was recorded. A baseline ankle/brachial systolic blood pressure 
index was recorded in both legs using the ipsilateral arm. 
Intraprocedural data included the type of procedure being 
performed, size of arterial sheath, dose of heparin given and 
dose of protamine given if any (allowed only for manual 
hemostasis patients). An activated clotting time was measured 
just before sheath removal. Two different types of machines 
were used for this measurement at he various institutions. The 
mean values were nearly identical for the two methods, and the 
results were therefore pooled and considered equivalent. 
At sheath removal, the time between sheath insertion and 
sheath removal was noted. The time to complete hemostasis 
was observed. For group I, this consisted of the time from 
device deployment to an absence of bleeding. For group II, 
hemostasis time was measured by partially releasing manual 
pressure very 10 rain beginning 15 rain after sheath removal in 
accordance with standard practice. The average of the first 
time that no bleeding occurred and the previous check time 
was taken as the time to hemostasis. If bleeding occurred later, 
this was also noted, and any additional hemostasis time was 
added to the original time. 
The following were recorded at 15-rain intervals for 1 h, 
then hourly for 4 h, then every 4 h for 24 h: pulse, blood 
pressure, presence or absence of groin bleeding, pain, hema- 
toma and peripheral pulses. A follow-up ankle/brachial index 
was recorded at 24 h. 
Before the procedure and at 24 h after sheath removal, 
duplex Doppler ultrasound examination of the common fem- 
oral artery and its bifurcation was performed. Attention was 
given to arterial size, presence of atherosclerosis and distur- 
bance of flow. At the follow-up examination, the intravascular 
anchor was again imaged, when possible, and patients were 
examined for the presence or absence of hematoma, pseudo- 
aneurysm, or intraarterial fi ling defect suggesting thrombus. 
After discharge from the hospital, telephone follow-up was 
performed. A return visit and examination was accomplished 
approximately 8 weeks after the procedure, including ultra- 
sound reexamination. During this time, repeat arterial access 
using the same site was discouraged. 
Complications. The following were noted as complica- 
tions: bleeding = any external blood loss after device deploy- 
ment, ->30 min of manual pressure required or any late 
bleeding, whether or not a measurable decrease in hematocrit 
occurred or transfusion was necessary; hematoma = any 
palpable mass; pseudoaneurysm = periarterial mass detected 
by physical examination or ultrasound-containing Doppler- 
detected flow. Loss of pulse, infection and clinical evidence of 
leg ischemia were also considered complications. Device fail- 
ure was not counted as a complication itself, unless one of 
these criteria was also met. 
Statistical analysis. All data were stored using FoxBase+/ 
MAC software (Fox Software) and analyzed using StatView 
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Table 1. Baseline Characteristics of 435 Study Patients 
Device Manual 
Group Group p 
(n = 218) (n = 217) Value 
Age (yr) 61 + 11 62 _+ 11 NS 
Male/female (%) 73/27 72/28 NS 
Cath/angioplasty (%) 77/23 70/30 NS 
Diabetes (%) 16 18 NS 
Hypertension (%) 46 46 NS 
Aspirin use (%) 65 66 NS 
Data presented are mean value _+ SD or percent of patients. Cath = cardiac 
catheterization. 
4.01 software (Abacus Concepts) running on a Macintosh 
Quadra 700 (Apple Computer). Comparisons of nominal data 
were done using chi-square tests. Unpaired comparisons of 
continuous data were done using the nonparametric Mann- 
Whitney U test because, in most cases, the data were not 
normally distributed. Results are presented as mean value _+ 
SD; p = 0.05 was considered significant. 
Results 
A total of 435 patients were randomized ateight participat- 
ing centers. Of these, 320 underwent diagnostic atheteriza- 
tion, and the other 115 underwent interventional procedures. 
Four patients were randomized but excluded (three had a 
preexisting hematoma before sheath removal; one underwent 
immediate bypass urgery without removal of the catheteriza- 
tion sheaths). 
Primary results. Group I included 218 patients who re- 
ceived hemostasis using the device; group II included 217 
patients who received the manual pressure control. Table 1 
summarizes the baseline characteristics ofboth groups. There 
were no significant differences between them. 
Table 2 shows the results of arterial sheath removal and the 
Table 2. Results of Arterial Sheath Removal and Incidence 
of Complications 
Device Manual p 
Group Group Value 
ACT (s) 176 _+ 69 156 _+ 53 0.005 
Dwell time (min) 150 _+ 336 261 _+ 447 NS 
Time to hemostasis (rain) 2.5 _+ 15.2 15.3 -+ 11 .7  <0.0001 
Ankle/braehial ratio 1.04 _+ 0.11 1.06 _+ 0.10 NS 
before hemostasis 
Ankle/brachial ratio after 1.03 _+ 0.10 1.04 _+ 0.10 NS 
hemostasis 
Complications 
Bleeding 15 (7%) 33 (15%) 0.007 
Hematoma 5 (2%) 12 (6%) 0.08 
Vascular 7 (3%) 5 (2%) NS 
Any complication 27 (12%) 40 (18%) 0.08 
Data presented are mean value _+ SD or number (%) of patients. ACT = 
activated clotting time; Dwell time - elapsed clock time between sheath 
insertion and removal; Vascular = pseudoaneurysm or artcriovenous fi tula. 
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Figure 3. Time required to achieve initial hemostasis. Hemostasis 
required <5 rain in most patients in the device group. 
incidence of complications. Time to hemostasis was consider- 
ably shorter in group I despite higher levels of anticoagulation 
reflected in the longer activated clotting time (Fig. 3). Seventy- 
six percent of group I patients experienced immediate (within 
1 rain) hemostasis. Complication rates were lower in group I
for the occurrence of bleeding (7% vs. 15%, p = 0.007), 
hematoma (2% vs. 6%, p = 0.08) and any complication (12% 
vs. 18%, p = 0.08) (Fig. 4). There was no difference in the 
incidence of pseudoaneurysm or arteriovenous fi tula forma- 
tion, the overall rate of which was 2.8%. There was no change 
in either group in the ankle/brachial index. Loss of pulse, 
infection and clinical evidence of leg ischemia did not occur in 
any patient in this study. (One incident of infection occurred in 
a nonrandomized pilot study patient and is not discussed here. 
In this patient, strict sterile technique was not followed during 
device deployment.) 
In 8 group I patients, device deployments were unsuccess- 
ful; the deployment success rate was therefore 96% (211 of 
219). All of these nondeployments occurred with an early 
version of the device, and all resulted in successful manual 
hemostasis. These patients were retained for analysis in group 
I. The subsequent device used throughout most of this trial 
incorporated modifications to the collagen and anchor. None 
of these devices failed to deploy. In a single group I patient, he 
Figure 4. Incidence of complications: Any = patients in whom any 
complication occurred; Vascular = pseudoaneurysm or arteriovenous 
fistula. 
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k, B 
Figure 5. Ultrasound appearance of the device. A, Common femoral 
artery (CFA) before device deployment. B, Common femoral artery 24 h 
after device d ployment. Intravascular anchor isvisible as a short, bright 
line against the superior border of the vessel. The collagen plug is not 
visible. C, At 4-week follow-up study, there is no evidence of arterial 
compromise, and the anchor has almost disappeared. RT = right. 
C 
intravascular nchor broke and was lost without sequelae. This 
was considered a complication. 
Ultrasound findings. Ultrasound scanning of the femoral 
artery access site was used as a preprocedural screening 
method to minimize local factors that could influence the 
results of the study. Follow-up duplex ultrasound to scan for 
subclinical complications was performed within 24 h of sheath 
removal, and again 60 days later. The anchor and collagen, 
which were frequently visible on 24-h studies, were virtually 
undetectable by 60 days, demonstrating that the device was 
absorbed uneventfully and without significant inflammatory 
response. Figure 5 shows an example of the ultrasound appear- 
ance of the common femoral artery before and at 24 h and 4 
weeks after device deployment. 
Results in patients undergoing interventional procedures. 
Because previous tudies (3) have indicated a higher rate of 
access ite complications after interventional procedures, it is 
of interest o analyze the use of the device in this patient 
subgroup. As indicated in Table 3, 46 patients in group I and 
63 in group II had interventional procedures. In both groups 
>11,500 U of heparin were given during the procedure, but 
owing to a longer sheath dwell-time in group II, the manual 
hemostasis group had a shorter activated clotting time at the 
time of sheath removal (155 _+ 48 vs. 213 _+ 89 s). Nevertheless, 
hemostasis time was considerably and significantly shorter with 
use of the device (3.5 --- 8.5 vs. 19.6 + 12.6 min). There were 
also significantly fewer complications in the device group. 
Results in patients undergoing diagnostic catheterization. 
Results were also analyzed separately for those patients un- 
dergoing diagnostic angiography. The results of this retrospec- 
tive analysis are presented in Table 4. The manual hemostasis 
group received a larger dose of heparin, but, like the patients 
having interventional procedures, they had their sheaths in 
place for a longer time and, as a result, had a shorter activated 
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Table 3. Results in Patients Undergoing Interventional Procedures 
Device Group Manual Group p 
(n = 46) (n = 63) Value 
Heparin dose (U) 11,740 + 5,200 11,820 _+ 4,300 NS 
Dwell time (min) 465 _+ 523 662 _+ 421 0.002 
ACT (s) 213 _+ 89 155 -+ 48 <0.0001 
Time to hemostasis (rain) 3.5 + 8.5 19.6 _+ 12.6  <0.0001 
Complications 
Bleeding 6 (13%) 16 (25%) 0.007 
Hematoma 0 7 (11%) 0.02 
Vascular 1 (2%) 1 (2%) NS 
Any complication 7 (15%) 20 (32%) 0.05 
Data presented are mean value + SD or number (%) of patients. Abbrevi- 
ations as in Table 2. 
clotting time at the time of sheath removal than the device 
group. Nevertheless, the time to hemostasis was significantly 
shorter in the device group (2.3 -+ 16.7 vs. 13.6 _+ 11.0 min). 
Complication rates for the two groups were similar, except for 
a trend suggesting a higher incidence of bleeding in the manual 
group. 
Effect of gender. The effect of gender on the results was 
analyzed. There were no baseline differences between men and 
women except hat the men received a significantly higher 
mean dose of heparin. Nevertheless, there were no significant 
differences between men and women in time to hemostasis or 
incidence of any complications. 
Influence of sheath size on complications. Table 5 shows 
the results of analysis of the manual pressure (group II) by 
sheath size. The use of 6F sheaths was associated with a 
significantly lower incidence of bleeding and overall complica- 
tions than use of 7F and 8F sheaths. By comparison, use of the 
hemostasis device yielded complication rates very similar to 
those found with 6F sheaths and manual hemostasis, despite 
the fact that all devices in this study were deployed through an 
8F sheath. 
Effects of heparin. Heparin was not administered to all 
patients in this study, which represents a potential confounding 
factor. Table 6 shows that in patients receiving the hemostasis 
device, use of heparin did not significantly increase the corn- 
Table 4. Results in Patients Undergoing Diagnostic Procedures 
Device Manual 
Group Group p 
(n = 168) (n = 152) Value 
Heparin dose (U) 3,460 -+ 3,240 4,180 + 4,093 NS 
Dwell time (min) 56 _+ 171 99 +- 347 0.03 
ACT (s) 166 + 58 156 _+ 55 NS 
Time to bemostasis (min) 2.3 +_ 16.7 13.6 _+ 11 .0  <0.0001 
Complications 
Bleeding 9 (5%) 17 (11%) 0.06 
Hematoma 5 (3%) 5 (3%) NS 
Vascular 6 (4%) 4 (3%) NS 
Any complication 20 (12%) 20 (13%) NS 
Data presented are mean value + SD or number (%) of patients. Abbrevi- 
ations as in Table 2. 
Table 5. Influence of Sheath Size on Complications 
Device Manual Group 
Group 
(all 8F) 6F 7F 8F p 
(n=218) (n=48)  (n=42)  (n=61)  Value 
Bleeding 15 (7%) 3 (4%) 12 (21%) 17 (20%) 0.004 
Hematoma 5 (2%) 3 (4%) 2 (4%) 6 (7%) NS 
Vascular 7 (3%) 1 (1%) 3 (5%) 1 (1%) NS 
Any complication 27 (12%) 5 (6%) 14 (25%) 20 (24%) 0.005 
Data presented are number (%) of patients. Vascular pseudoaneurysm or 
arteriovenous fi tula. 
plication rate. In the manual group, by contrast, heparin use 
doubled the mean time to hemostasis and increased the overall 
complication rate from 6% to 27%. 
Discuss ion  
The present report describes an arterial hemostatic device 
that appears to offer a clear advantage over manual methods in 
terms of rapidity of hemostasis and a lower incidence of 
complications. This advantage is apparent in both diagnostic 
and interventional procedures and is especially evident during 
anticoagulation. 
The present device differs in several respects from another 
recently described 180-rag bovine collagen plug device that is 
implanted into the external aspect of the arterial wall after 
dilation of the skin and subcutaneous tissue (12,13). By 
contrast, he present device contains an 18-mg collagen plug 
and is delivered through an arterial sheath; no additional tissue 
dilation is required. No firm manual pressure is required to 
deliver the device; on the contrary, it is deployed uring a 
pullback maneuver, which should decrease the likelihood of 
intraarterial deployment of the collagen plug. Once in place, 
the device provides ecure sealing of the arterial wall defect 
both from inside and outside. 
Subgroup analysis indicates particular usefulness of the 
device in patients who had received heparin and in those 
undergoing interventional procedures. In these subgroups, the 
complication rate was reduced by >50% with use of the device. 
These post hoc analyses must be interpreted with caution, but 
they suggest a promising role for the hemostatic device in 
patients at high risk for access site complications. When 
heparin is administered during diagnostic atheterization, the 
results suggest that protamine administration may not be 
necessary tosafely achieve hemostasis when the present device 
is used. The risk of severe allergic reaction to protamine would 
thus be avoided (16,17). 
It is possible that the dwell time of the sheath contributes to
access site complications. Our data seem to support this 
possibility, inasmuchas the device group had in every analysis a
shorter dwell time than the manual group. However, within the 
manual and device groups, there was no correlation between 
sheath dwell and hemostatic times, nor was there any signifi- 
cant difference in dwell times between patients with and 
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Table 6. Effect of Heparin Administration 
Device Group Manual Group 
With Without With Without 
Heparin Heparin p Heparin Heparin p 
(n = 121) (n = 97) Value (n = 124) (n = 93) Value 
ACT (s) , 204 + 77 142 _+ 35 <0.0001 173 _+ 57 134 _+ 37 <0.0001 
Time to hemostasis 1.9 _+ 518 3.1 + 21.9 NS 19.6 _+ 12.6 9.7 -+ 7.4 <0.0001 
Complications 
Bleeding 7 (6%) 8 (8%) NS 30 (24%) 3 (3%) <0.0001 
Hematoma 2 (2%) 3 (3%) NS 10 (8%) 2 (2%) 0.06 
Vascular 5 (4%) 2 (2%) NS 3 (2%) 2 (2%) NS 
Any complication 15 (12%) 12 (12%) NS 34 (27%) 6 (6%) <0.0001 
Data presented are mean value _+ SD or number (%) of patients. Abbreviations as in Table 2. 
• without complications. It therefore seems unlikely that dwell 
time contributed to the significant differences found between 
the manual and device groups. 
Previous studies (18,19) have suggested a low incidence of 
access ite complications when smaller sheaths are used. The 
role of sheath size is confirmed by the results of the present 
study that suggest that in the manual group 6F sheaths are 
safer than 7F or 8F sheaths (5F catheters were not used). The 
finding that complication rates with the present hemostatic 
device delivered through an 8F sheath were comparable to6F 
manual hemostasis suggests that the search for ever-smaller 
catheters, with the attendant limitations of maneuverability 
and opacification (18), may not be necessary once a method is 
found that can secure rapid, reliable and safe arterial hemo- 
stasis on catheter removal. 
Study limitations. Early ambulation with use of the me- 
chanical device was not tested in the present study. However, 
the average time to hemostasis of 2.3 min, coupled with a 
significantly reduced complication rate, does suggest that early 
ambulation is feasible. If this is confirmed in future studies, use 
of the device may contribute to the safe performance of 
outpatient cardiac atheterization. 
The effects of manual versus mechanical clamp hemostasis 
in the manual group were not addressed in our study. The 
number of patients in whom the clamp was used was small (6% 
of group II). There was no significant difference in complica- 
tion rates between patients with manual hemostasis and those 
with clamp hemostasis. However, the study group was too 
small to allow clinical conclusions regarding the safety of 
manual versus mechanical c amp hemostasis. 
This study was not designed to test use of the device in 
patients with peripheral vascular disease, bleeding diatheses, 
severe hypertension, marked obesity or preexisting hemato- 
mas, all of which increase the risk of vascular complications. 
However, it will be of interest to see whether this or any other 
device provides increased safety in these clinical settings. 
The somewhat higher proportion of patients undergoing 
angioplasty ingroup II might predispose this group to a higher 
complication rate. However, when interventional and diagnos- 
tic cases were analyzed separately, a difference in complication 
rates favoring the device group was still present (Tables 3 and 
4) despite lower activated clotting times in the manual group. 
Therefore, it appears likely that the differences observed were 
due to the use of the hemostatic device in group I patients. 
We report an unusually high overall incidence of groin 
complications (18% in the manual group). This incidence was 
determined using stringent criteria. For the device group, any 
bleeding, however slight, was included as a complication 
because this represents less than optimal performance of the 
device. The need to hold pressure for ->30 min was also 
considered a bleeding complication. Prolonged groin pressure 
is uncomfortable for patients and represents an additional 
investment ofpersonnel time. Four patients with a pseudoan- 
eurysm and one with an arteriovenous fi tula were not treated, 
and their condition had resolved spontaneously b  the time of 
late follow-up; the other seven patients underwent ultrasound- 
guided compression therapy. No patient required surgical 
repair. To our knowledge, no previous tudy has investigated 
the incidence of access ite complications using routine ultra- 
sound examination. It seems likely that he incidence of access 
site complications i  higher than previously noted after manual 
hemostasis, although some of these may not be clinically 
significant. 
The potential economic impact of use of the present device 
was also not addressed here. Cost savings might be generated 
through faster hemostasis (which saves personnel time) as well 
as through reduction in complications and in the cost of their 
treatment. We believe that this is the first hemostatic method 
to demonstrate improvement over manual methods in terms of 
both time and complications. The economic implications will 
be explored in future studies. 
Conclusions. The sheath-deployed, bioabsorbable device 
described herein provides asafe and effective means of obtain- 
ing arterial hemostasis after cardiac catheterization proce- 
dures. It leads to fewer access ite complications than manual 
hemostasis, even in the presence of anticoagulation a d after 
interventional procedures. This device may prove useful in 
other coronary interventional settings where access complica- 
tions are frequent. Further study of the device is warranted in
combination with early ambulation, and its use with large 
sheaths and intense anticoagulation should be investigated. 
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